Drug Trial Radar · NCT00713310
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Apr 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Dec 2008
Primary completion
Mar 2011
Study completion Mar 2011
Sponsor
- Lead sponsor
- Warner ChilcottIndustry
- Sponsor type
- Industry
- First posted
- Jul 11, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this study is to assess the safety and efficacy of high dose and low dose Asacol administered as 400 mg delayed-release tablets given every 12 hours for 6 weeks to children and adolescents with mildly-to-moderately active ulcerative colitis.
Conditions
- Ulcerative Colitis
Interventions
Asacol 400 mgDrug
High dose: 17-\<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-\<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-\<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM
Asacol 400 mgDrug
Low dose: 17-\<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-\<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-\<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat PopulationTime frame: Baseline and 6 weeks
Locations
42 sites in 5 countries. Site status is shown where the registry gives one.
Research Facility
Birmingham, Alabama
Research Facility
Phoenix, Arizona
Research Facility
Loma Linda, California
Research Facility
San Diego, California
Research Facility
San Francisco, California
Research Facility
San Francisco, California
Research Facility
Washington D.C., District of Columbia
Research Facility
Gainesville, Florida
Research Facility
Park Ridge, Illinois
Research Facility
Louisville, Kentucky
Research Facility
Boston, Massachusetts
Research Facility
Worcester, Massachusetts
Research Facility
Kansas City, Missouri
Research Facility
Omaha, Nebraska
Research Facility
Mays Landing, New Jersey
Research Facility
Buffalo, New York
Research Facility
New Hyde Park, New York
Research Facility
Youngstown, Ohio
Research Facility
Portland, Oregon
Research Facility
Chattanooga, Tennessee
Research Facility
Knoxville, Tennessee
Research Facility
Fort Worth, Texas
Research Facility
Houston, Texas
Research Facility
San Antonio, Texas
Research Facility
Norfolk, Virginia
Research Facility
Huntington, West Virginia
Research Facility
Halifax, Nova Scotia, Canada
Research Facility
Hamilton, Ontario, Canada
Research Facility
London, Ontario, Canada
Research Facility
Ottawa, Ontario, Canada
Research Facility
Montreal, Quebec, Canada
Research Site
Rijeka, Croatia, Croatia
Research Site
Zagreb, Croatia, Croatia
Research Site
Bialystok, Poland, Poland
Research Site
Bydgoszcz, Poland, Poland
Research Site
Krakow, Poland, Poland
Research Site
Lodz, Poland, Poland
Research Site
Warsazawa, Poland, Poland
Research Site
Wroclaw, Poland, Poland
Research Site
Bucharest, Romania, Romania
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.